Canaccord lowered the firm’s price target on Cybin (CYBN) to $70 from $73 and keeps a Buy rating on the shares. The firm noted they recently reported its F4Q25 results and operating expenses came in close to estimates. The key update were that the company is on track to complete its Phase 2 study for CYB004 (deuterated DMT) for generalized anxiety disorder (GAD) in mid- C2025E; and report Phase 3 data for CYB003 (deuterated psilocin analog) for major depressive disorder (MDD) in C2026E. Canaccord continues to believe Cybin is significantly undervalued ahead of data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Inc. Reports on Governance and Compliance
- Psychedelic: atai Life Sciences, Beckley Psytech report BPL-003 study results
- Cybin’s Strong Position in Psychedelic Neuropsychiatry: Buy Rating Backed by Advancements and Financial Flexibility
- Options Volatility and Implied Earnings Moves Today, July 01, 2025
- Cybin Inc. Advances Mental Health Innovations with Strategic Partnerships and Clinical Progress